From : Tamar Gabunia </O=EXCHORGANIZATION/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=E6CA04F38EC94D0CADAB9CBDF90FCDDE-TAMAR G>
To : V.kvaratskhelia@outlook.com
Subject : FW: [EXTERNAL] request from MoH Georgia
Received On : 13.04.2020 12:00
-----Original Message----- From: Tamar Gabunia Sent: 9 April, 2020 15:52 To: 'Graeme Robertson' ; Aysan Murtezaoglu ; Maia Nikoleishvili Cc: Amina Rafiki Subject: RE: [EXTERNAL] request from MoH Georgia Dear Graeme Thanks for your follow up on this. Unfortunately we've received a negative reading on our request. Please find below. We are now discussing with WHO the possibility to join the global Solidarity Trial. Hopefully this will allow us to access promising treatments for COVID19. With kind regards Tamar From: GileadClinicalTrials Sent: Friday, April 3, 2020 11:40 AM To: Maia Nikoleishvili Subject: RE: request from MoH Georgia Dear Mrs. Nikoleishvili, Thank you for your inquiry regarding potential participation in our COVID-19 clinical trials. At this point of time, Gilead has reached its capacity and cannot add any new sites to the ongoing studies (NCT04292899 [EudraCT 2020-000841-15) and NCT04292730 [EudraCT 2020-000842-32). Information regarding Clinical Trials Gilead Sciences is currently conducting and that may actively be recruiting are published in Clinical Trial Registries such as ClinicalTrials.gov (www.clinicaltrials.gov) and EU-CTR (https://www.clinicaltrialsregister.eu/ctr-search/search). Kind Regards, Gilead Sciences Clinical Trials | Clinical Trials | Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404 | -----Original Message----- From: Graeme Robertson [mailto:Graeme.Robertson@gilead.com] Sent: 9 April, 2020 15:13 To: Tamar Gabunia ; Aysan Murtezaoglu ; Maia Nikoleishvili Cc: Amina Rafiki Subject: RE: [EXTERNAL] request from MoH Georgia Dear Tamar, Did you get a response from Gilead on your request you sent to this e-mail address coronavirus.response@gilead.com I am copying my colleague Amina who is collating all the requests from my region. Thank you and best wishes Graeme -----Original Message----- From: Tamar Gabunia Sent: 17 March 2020 14:16 To: Aysan Murtezaoglu ; Graeme Robertson ; Maia Nikoleishvili Subject: RE: [EXTERNAL] request from MoH Georgia Thanks a lot! -----Original Message----- From: Aysan Murtezaoglu [mailto:Aysan.Murtezaoglu@gilead.com] Sent: 17 March, 2020 17:50 To: Tamar Gabunia ; Graeme Robertson ; Maia Nikoleishvili Subject: RE: [EXTERNAL] request from MoH Georgia Of course coronavirus.response@gilead.com and internally I will contact few colleagues to let them know that a request from Georgia will be coming soon. Best regards Aysan -----Original Message----- From: Tamar Gabunia Sent: 17 Mart 2020 Salı 16:09 To: Aysan Murtezaoglu ; Graeme Robertson ; Maia Nikoleishvili Subject: RE: [EXTERNAL] request from MoH Georgia Dear Aysan I've checked with Dr Amira, no request has been submitted so far to the e-mail address. Could you please kindly share the address with me and I'll follow up with the request submission. Many thanks! პატივისცემით, თამარ გაბუნია მინისტრის პირველი მოადგილე Sincerely, Tamar Gabunia, MD, MPH First Deputy Minister -----Original Message----- From: Aysan Murtezaoglu [mailto:Aysan.Murtezaoglu@gilead.com] Sent: 17 March, 2020 17:03 To: Tamar Gabunia ; Graeme Robertson ; Maia Nikoleishvili Subject: RE: [EXTERNAL] request from MoH Georgia Dear Tamar That would be great On 13th of March I also shared the same e mail address with Dr Tengiz and Dr Amiran so it will be good to know if Gilead has been already contacted or not. As soon as I have an information from you I will contact my collegaues. Best regards Aysan -----Original Message----- From: Tamar Gabunia Sent: 17 Mart 2020 Salı 15:58 To: Graeme Robertson ; Maia Nikoleishvili Cc: Aysan Murtezaoglu Subject: RE: [EXTERNAL] request from MoH Georgia Dear Graeme Many thanks for your reply and guidance on this. We'll consult Dr Sergeenko to find out if the submission has been made via e-mail. With kind regards Tamar პატივისცემით, თამარ გაბუნია მინისტრის პირველი მოადგილე Sincerely, Tamar Gabunia, MD, MPH First Deputy Minister -----Original Message----- From: Graeme Robertson [mailto:Graeme.Robertson@gilead.com] Sent: 17 March, 2020 16:48 To: Maia Nikoleishvili Cc: Tamar Gabunia ; m.tskitishvili@mrdi.gov.ge; Aysan Murtezaoglu Subject: Re: [EXTERNAL] request from MoH Georgia Dear Maia, Thank you for your mail, my colleague Aysan in copy on this mail is managing requests from the region and will ensure your request gets to the right people in our clinical research teams. In the meantime did you contact Gilead through the Corona virus response e mail address that I gave to David Seergenko late last week. Aysan will also be able to guide you through the compassionate use supply of drug. I wish you all the best in this turbulent times Please let me know if you require any further assistance Best wishes Graeme Sent from my iPhone On 16 Mar 2020, at 17:39, Maia Nikoleishvili wrote:  Dear Graeme, Hope you are doing well! I would like to kindly provide you with a letter signed by the Minister – Ms. Ekaterine Tikaradze regarding the possibility of engagement in the study of Remdesivir for the treatment of the patients with severe acute respiratory syndrome of COVID-19. We kindly ask you to assist us in obtaining the response to the request addressed to Dr. Daniel O'Day. Thank you in advance for continued support and partnership. Looking forward to hearing from you. With best regards, Maia Nikoleishvili MPA Acting Head of International Relations and Protocol Division of Administration Ministry of IDPs from the Occupied Territories, Labour, Health and Social Affairs of Georgia Address: 144 Tsereteli ave., 0159 Tbilisi, Georgia Tel.: +995 32 2510034 (0803) Cell phone: +995 577272713 E-mail: mnikoleishvili@moh.gov.ge DISCLAIMER If you have received this message in error, please contact the sender immediately by return e-mail and notify the sender and then delete this message (including any attachments) from your system. This communication and any attachments contain information which is confidential and may also be legally privileged. It is for the exclusive use of the intended recipient(s). If you are not the intended recipient(s) please note that any form of disclosure, distribution, copying or use of this communication or the information in it or in any attachments is strictly prohibited and may be unlawful. If your e-mail contains any personal information then we will process this according to our Privacy Statement located on Gilead.com. E-mail communications cannot be guaranteed to be secure or error free, as information could be intercepted, corrupted, amended, lost, destroyed, arrive late or incomplete, or contain viruses. Gilead does not accept liability for any such matters or their consequences. Anyone who communicates with Gilead by e-mail is taken to accept the risks in doing so. Gilead has taken every reasonable precaution to ensure that any attachment to this e-mail has been swept for viruses. However, Gilead cannot accept liability for any damage sustained as a result of viruses and would advise that you carry out your own virus checks before opening any attachment. Gilead Sciences Europe Ltd ; Registered as a limited company in England and Wales ; Registered number 5510315 Registered office: South Building ; 2 Roundwood Avenue ; Stockley Park ; Uxbridge ; UB11 1AF ; England If you have received this message in error, please contact the sender immediately by return e-mail and notify the sender and then delete this message (including any attachments) from your system. This communication and any attachments contain information which is confidential and may also be legally privileged. It is for the exclusive use of the intended recipient(s). If you are not the intended recipient(s) please note that any form of disclosure, distribution, copying or use of this communication or the information in it or in any attachments is strictly prohibited and may be unlawful. If your e-mail contains any personal information then we will process this according to our Privacy Statement located on Gilead.com. E-mail communications cannot be guaranteed to be secure or error free, as information could be intercepted, corrupted, amended, lost, destroyed, arrive late or incomplete, or contain viruses. Gilead does not accept liability for any such matters or their consequences. Anyone who communicates with Gilead by e-mail is taken to accept the risks in doing so. Gilead has taken every reasonable precaution to ensure that any attachment to this e-mail has been swept for viruses. However, Gilead cannot accept liability for any damage sustained as a result of viruses and would advise that you carry out your own virus checks before opening any attachment. If you have received this message in error, please contact the sender immediately by return e-mail and notify the sender and then delete this message (including any attachments) from your system. This communication and any attachments contain information which is confidential and may also be legally privileged. It is for the exclusive use of the intended recipient(s). If you are not the intended recipient(s) please note that any form of disclosure, distribution, copying or use of this communication or the information in it or in any attachments is strictly prohibited and may be unlawful. If your e-mail contains any personal information then we will process this according to our Privacy Statement located on Gilead.com. E-mail communications cannot be guaranteed to be secure or error free, as information could be intercepted, corrupted, amended, lost, destroyed, arrive late or incomplete, or contain viruses. Gilead does not accept liability for any such matters or their consequences. Anyone who communicates with Gilead by e-mail is taken to accept the risks in doing so. Gilead has taken every reasonable precaution to ensure that any attachment to this e-mail has been swept for viruses. However, Gilead cannot accept liability for any damage sustained as a result of viruses and would advise that you carry out your own virus checks before opening any attachment. DISCLAIMER If you have received this message in error, please contact the sender immediately by return e-mail and notify the sender and then delete this message (including any attachments) from your system. This communication and any attachments contain information which is confidential and may also be legally privileged. It is for the exclusive use of the intended recipient(s). If you are not the intended recipient(s) please note that any form of disclosure, distribution, copying or use of this communication or the information in it or in any attachments is strictly prohibited and may be unlawful. If your e-mail contains any personal information then we will process this according to our Privacy Statement located on Gilead.com. E-mail communications cannot be guaranteed to be secure or error free, as information could be intercepted, corrupted, amended, lost, destroyed, arrive late or incomplete, or contain viruses. Gilead does not accept liability for any such matters or their consequences. Anyone who communicates with Gilead by e-mail is taken to accept the risks in doing so. Gilead has taken every reasonable precaution to ensure that any attachment to this e-mail has been swept for viruses. However, Gilead cannot accept liability for any damage sustained as a result of viruses and would advise that you carry out your own virus checks before opening any attachment. Gilead Sciences Europe Ltd ; Registered as a limited company in England and Wales ; Registered number 5510315 Registered office: South Building ; 2 Roundwood Avenue ; Stockley Park ; Uxbridge ; UB11 1AF ; England